Cargando…

Efficacy and safety of the extracorporeal shockwave therapy in patients with postherpetic neuralgia: study protocol of a randomized controlled trial

BACKGROUND: Postherpetic neuralgia (PHN) is one of the most common types of chronic neuropathic pain, which seriously affects quality of the life because of pain severity and poor response to the currently available treatments. The main strategies for PHN management are medication and invasive inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Lu, Zhou, Ruihao, Sun, Fuguo, Weng, Yan, Ye, Ling, Yang, Pingliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346340/
https://www.ncbi.nlm.nih.gov/pubmed/32641142
http://dx.doi.org/10.1186/s13063-020-04564-z
_version_ 1783556387835478016
author Chen, Lu
Zhou, Ruihao
Sun, Fuguo
Weng, Yan
Ye, Ling
Yang, Pingliang
author_facet Chen, Lu
Zhou, Ruihao
Sun, Fuguo
Weng, Yan
Ye, Ling
Yang, Pingliang
author_sort Chen, Lu
collection PubMed
description BACKGROUND: Postherpetic neuralgia (PHN) is one of the most common types of chronic neuropathic pain, which seriously affects quality of the life because of pain severity and poor response to the currently available treatments. The main strategies for PHN management are medication and invasive interventional therapies; however, these approaches have many adverse effects, so it is important to find another effective and safe treatment for PHN. METHODS: A single-center, single-blind randomized clinical trial will evaluate 98 study participants randomized in a 1:1 ratio into control and experimental groups. The control group will receive conventional treatment including medication therapy and invasive interventional therapy. The experimental group will receive extracorporeal shockwave therapy (ESWT) in addition to conventional therapy. The primary outcome is pain intensity assessed on a visual analogue scale (VAS); the secondary outcomes are the following: quality of life assessed by the 36-Item Short-Form Health Survey (SF-36), psychological state for anxiety and depression measured by the Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS), and sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI). Assessors blinded to the randomization will collect data during the intervention period at baseline and weeks 1, 4, and 12. The plasma levels of tumor necrosis factor-α and interleukin-6 will be assessed before and after ESWT to explore the biochemical mechanisms of ESWT in the treatment of PHN. DISCUSSION: This randomized controlled trial will evaluate the effectiveness and safety of ESWT in patients with PHN and thus will provide clinical evidence for its use in the management of PHN and explore the potential biochemical mechanisms of this treatment. TRIAL REGISTRATION: www.ChiCTR.org.cn, identifier: ChiCTR1900025828. Registered on 10 September 2019
format Online
Article
Text
id pubmed-7346340
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73463402020-07-14 Efficacy and safety of the extracorporeal shockwave therapy in patients with postherpetic neuralgia: study protocol of a randomized controlled trial Chen, Lu Zhou, Ruihao Sun, Fuguo Weng, Yan Ye, Ling Yang, Pingliang Trials Study Protocol BACKGROUND: Postherpetic neuralgia (PHN) is one of the most common types of chronic neuropathic pain, which seriously affects quality of the life because of pain severity and poor response to the currently available treatments. The main strategies for PHN management are medication and invasive interventional therapies; however, these approaches have many adverse effects, so it is important to find another effective and safe treatment for PHN. METHODS: A single-center, single-blind randomized clinical trial will evaluate 98 study participants randomized in a 1:1 ratio into control and experimental groups. The control group will receive conventional treatment including medication therapy and invasive interventional therapy. The experimental group will receive extracorporeal shockwave therapy (ESWT) in addition to conventional therapy. The primary outcome is pain intensity assessed on a visual analogue scale (VAS); the secondary outcomes are the following: quality of life assessed by the 36-Item Short-Form Health Survey (SF-36), psychological state for anxiety and depression measured by the Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS), and sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI). Assessors blinded to the randomization will collect data during the intervention period at baseline and weeks 1, 4, and 12. The plasma levels of tumor necrosis factor-α and interleukin-6 will be assessed before and after ESWT to explore the biochemical mechanisms of ESWT in the treatment of PHN. DISCUSSION: This randomized controlled trial will evaluate the effectiveness and safety of ESWT in patients with PHN and thus will provide clinical evidence for its use in the management of PHN and explore the potential biochemical mechanisms of this treatment. TRIAL REGISTRATION: www.ChiCTR.org.cn, identifier: ChiCTR1900025828. Registered on 10 September 2019 BioMed Central 2020-07-08 /pmc/articles/PMC7346340/ /pubmed/32641142 http://dx.doi.org/10.1186/s13063-020-04564-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Chen, Lu
Zhou, Ruihao
Sun, Fuguo
Weng, Yan
Ye, Ling
Yang, Pingliang
Efficacy and safety of the extracorporeal shockwave therapy in patients with postherpetic neuralgia: study protocol of a randomized controlled trial
title Efficacy and safety of the extracorporeal shockwave therapy in patients with postherpetic neuralgia: study protocol of a randomized controlled trial
title_full Efficacy and safety of the extracorporeal shockwave therapy in patients with postherpetic neuralgia: study protocol of a randomized controlled trial
title_fullStr Efficacy and safety of the extracorporeal shockwave therapy in patients with postherpetic neuralgia: study protocol of a randomized controlled trial
title_full_unstemmed Efficacy and safety of the extracorporeal shockwave therapy in patients with postherpetic neuralgia: study protocol of a randomized controlled trial
title_short Efficacy and safety of the extracorporeal shockwave therapy in patients with postherpetic neuralgia: study protocol of a randomized controlled trial
title_sort efficacy and safety of the extracorporeal shockwave therapy in patients with postherpetic neuralgia: study protocol of a randomized controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346340/
https://www.ncbi.nlm.nih.gov/pubmed/32641142
http://dx.doi.org/10.1186/s13063-020-04564-z
work_keys_str_mv AT chenlu efficacyandsafetyoftheextracorporealshockwavetherapyinpatientswithpostherpeticneuralgiastudyprotocolofarandomizedcontrolledtrial
AT zhouruihao efficacyandsafetyoftheextracorporealshockwavetherapyinpatientswithpostherpeticneuralgiastudyprotocolofarandomizedcontrolledtrial
AT sunfuguo efficacyandsafetyoftheextracorporealshockwavetherapyinpatientswithpostherpeticneuralgiastudyprotocolofarandomizedcontrolledtrial
AT wengyan efficacyandsafetyoftheextracorporealshockwavetherapyinpatientswithpostherpeticneuralgiastudyprotocolofarandomizedcontrolledtrial
AT yeling efficacyandsafetyoftheextracorporealshockwavetherapyinpatientswithpostherpeticneuralgiastudyprotocolofarandomizedcontrolledtrial
AT yangpingliang efficacyandsafetyoftheextracorporealshockwavetherapyinpatientswithpostherpeticneuralgiastudyprotocolofarandomizedcontrolledtrial